Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating restated by analysts at B. Riley in a research report issued on Thursday, January 18th, Marketbeat Ratings reports. They presently have a $54.00 target price on the specialty pharmaceutical company’s stock. B. Riley’s price target indicates a potential upside of 45.16% from the company’s current price.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, January 10th. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Janney Montgomery Scott reiterated a “hold” rating and issued a $47.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Cowen reiterated a “buy” rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Finally, Jefferies Group reiterated a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $51.36.
Shares of Supernus Pharmaceuticals (SUPN) traded up $0.05 during trading hours on Thursday, hitting $37.20. The company’s stock had a trading volume of 796,967 shares, compared to its average volume of 757,477. Supernus Pharmaceuticals has a fifty-two week low of $24.65 and a fifty-two week high of $50.04. The stock has a market capitalization of $1,910.00, a price-to-earnings ratio of 33.82 and a beta of 1.08.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The business’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities research analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.
In related news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Victor Vaughn sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The disclosure for this sale can be found here. Insiders sold 165,750 shares of company stock valued at $7,133,973 in the last quarter. 6.70% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its stake in Supernus Pharmaceuticals by 91.4% in the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its stake in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares in the last quarter. Victory Capital Management Inc. raised its stake in Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 517 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $188,000. 98.71% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/10/supernus-pharmaceuticals-supn-rating-reiterated-by-b-riley.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.